CV NEWS FEED // The Supreme Court has set March 26 as the date it will hear oral arguments in a highly anticipated case regarding the legality of the abortion-inducing drug mifepristone.
The Court announced it would hear the Food and Drug Administration (FDA) v. Alliance for Hippocratic Medicine mid-last month.
“The FDA’s own label for these drugs says that roughly one in 25 women who take them will end up in the emergency room,” said Alliance Defending Freedom (ADF) Senior Counsel Erin Hawley, who represents the Alliance for Hippocratic Medicine. “The agency’s removal of in-person doctor visits and consistent, ongoing care has subjected more women to suffering severe, even life-threatening, medical conditions.”
“Regardless of Americans’ beliefs about abortion, no one should be okay with the FDA leaving girls to take these high-risk drugs all alone,” added Hawley, who is married to Sen. Josh Hawley, R-MO.
POLITICO reported that the case “is to be the Supreme Court’s first significant return to the abortion issue since” they decided Dobbs v. Jackson on June 24, 2022.
As CBS reported, later that year “doctors and groups led by the Alliance for Hippocratic Medicine filed a lawsuit in federal district court in Amarillo, Texas, challenging the FDA’s 2000 approval of mifepristone, as well as its changes starting in 2016.”
In April 2023, Texas-based U.S. District Judge Matthew Kacsmaryk “blocked the FDA’s 2000 approval of mifepristone and all subsequent actions from the agency that made it easier to obtain,” CBS went on:
The decision from Kacsmaryk set off a series of rulings from the courts after the Biden administration appealed to the U.S. Court of Appeals for the 5th Circuit. The appeals court first narrowed Kacsmaryk’s order, reinstating mifepristone’s 2000 approval but tightening the rules for its use
POLITICO noted: “The appellate court’s ruling is on hold for now, meaning there will be no change in how the pills are distributed until the Supreme Court issues its decision, most likely in June.”
Per FOX, in addition to ending mail-ordering of mifepristone, the 5th Circuit “shorten[ed]” the “time during which mifepristone can be used in pregnancy” from ten weeks’ to seven weeks’ gestation.
POLITICO further noted that the “Supreme Court is also set to hear arguments in April on another abortion case related to hospitals’ obligation to provide abortions to patients experiencing a medical emergency.”